Symposium
Some of the greatest advances of science were raised on the second half of the 20th century (e.g. Recombinant DNA and Hybridoma technology) and now that they got improved, promising new diagnostics and therapeutics tools for cancer research and treatment are emerging. The Summer Symposium will bring some of these new aspects presented by the very own, renowned scientists who developed and are still working on them.
january, 29th to 31st, 2009
Address: Instituto de Ciências da Saúde- Universidade Federal da Bahia
Av. Reitor Miguel Calmon, S/N - Vale do Canela - Salvador, Bahia, Brasil
Lecturers
International Lecturers
Dr. Carl Borrebaeck
Professor of Immunology, Department of Immunotechnology and Director of the Create Health – Centre for Clinical Cancer Research, Lund University, Sweden.
Main research focus: New aspects of cancer diagnostics and detection of serum molecular signatures by using monoclonal antibodies microarrays and gene-directed proteomics.
Dra. Lupe Salazar
Researcher of the Tumor Vaccine Group, Washington University, USA.
Main research focus: Phase I and II Clinical trials in mammary and ovarian cancer patients by using adoptive therapy of T Lymphocytes targeted against the oncogenic Her2-Neu antigen as well as DNA vaccines coding the same gene.
Dr. Volker Schirrmacher
Researcher of the Deutsches Krebsforschungszentrum (German Center of Cancer Research), in Heidelberg, Germany.
Main research focus: Adoptive therapy using ex-vivo tumoral antigens stimulated-T lymphocytes and the therapeutic action of modified oncolytic viruses carrying cytokine genes.
Dr. Pramod Srivastava
Full Professor of Immunology and Director of the Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut, USA.
Main research focus: Phase I clinical trials in chronic myeloid leukemia (CML) and ovarian cancer based on HSPs-associated peptides extracted from cancer cells as therapeutic vaccines.
National Lecturers
Dr. José Alexandre Barbuto
Professor of Immunology, São Paulo University (USP), Brazil.
Main research focus: The role of dendritic cells (DCs) in cancer and its use on the immunotherapy of melanoma and renal cancers.
Dr. Carlos Gil Ferreira
Research Director of the Brazilian National Institute of Câncer (INCA), Rio de Janeiro, Brazil.
Main research focus: Molecular oncology, particularly on the development of new therapeutic drugs with anti-neoplastic activity and cancer prognostic factors.
Dr.Oswaldo Keith Okamoto
Professor of Experimental Neurology, São Paulo Federal University (UNIFESP), Brazil.
Main research focus: Cancer stem cells of the human central nervous system.
Program
29.01.2009
19:30 h – Opening: Dr. Naomar de Almeida Filho
Chanceller – Federal University of Bahia
20:00 h – Dr. Pramod Srivastava
“Role of peptides in the antigens presentation and immunostimulation ”
21:00 h – Cocktail
30.01.2009
8:30 h – Dr. Carl Borrebaeck
“Affinity oncoproteomic in cancer diagnosis”
9:30 h – Coffee Break
11:00 h - Dr. Volker Schirrmacher
“Modified oncolytic virus to use in cancer treatment”
14:30 h - Dr. Pramod Srivastava
“Chaperone-peptide complexes in immunotherapy of human cancer”
15:30 h – Coffee Break
16:00 h - Dra. Lupe Salazar
“T cells adoptive therapy after in vivo peptide HER2 stimulation”
17:00 h - Dr. Carlos Gil Ferreira
“Molecular oncology and development of new drugs for cancer treatment ”
31.01.2009
8:30 h – Dr. José Alexandre Barbuto
“Immunotherapeutic approaches in cancer with emphasis on dendritic cells”
9:30 h – Coffee Break
10:00 h – Dr. Carl Borrebaeck
“Discovery of a new biomarker for cancer, sox 11, using gene-directed Proteomics”
11:00 h Dr. Oswaldo Keith Okamoto
“Therapeutic targets in gliomas: molecular and cellular aspects”
Committee
Dr. Roberto Meyer
Dr. Edgard M. de Carvalho Filho
Dra. Songelí Freire
Dra Ivana Nascimento
Dr. Robert Schaer
Pós-graduando Adriano Alcântara